The multivalent toxoid vaccine candidate from LimmaTech Biologics AG is designed to prevent skin and soft-tissue infections ...

Staphylococcus aureus cultures in the Liu Lab. Credit: Kyle Dykes/ UC San Diego Health Sciences Researchers at UC San Diego ...

Staphylococcus aureus (S. aureus) is a major cause of skin and soft tissue infections that can sometimes lead to sepsis and ...

Belgium reported the case on December 18 in an adult traveler returning from an African country where the clade 1b virus ...

aureus. Fortunately, a number of new agents active against MRSA and other Gram-positive pathogens have been developed and introduced into the clinics. Linezolid, daptomycin and tigecycline are ...

“It is a pathogen in dire need of control because it causes significant morbidity and mortality not just in the United States ...

LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has grant ...

Innoviva (INVA) announced it has entered into an exclusive distribution and license agreement with Basilea Pharmaceutica for the commercialization of Zevtera, an advanced-generation cephalosporin ...

We are very pleased with our collaboration with Innoviva Specialty Therapeutics for the commercialization of Zevtera in the US. The company is a highly committed, focused and capable partner that ...

Each week, KFF Health News compiles a selection of the latest health research and news.